Survey of pediatricians in Germany reveals important challenges for possible implementation of meningococcal B vaccination  by Takla, Anja et al.
BS
p
A
a
b
a
A
R
R
1
A
A
K
N
M
A
I
C
S
1
(
a
T
a
(
s
d
f
r
o
o
4
o
m
s
(
H
h
0Vaccine 32 (2014) 6349–6355
Contents lists available at ScienceDirect
Vaccine
j our na l ho me page: www.elsev ier .com/ locate /vacc ine
rief  report
urvey  of  pediatricians  in  Germany  reveals  important  challenges  for
ossible  implementation  of  meningococcal  B  vaccination
nja  Taklaa,∗, Ole  Wichmanna, Judith  Kocha, Martin  Terhardtb,  Wiebke  Hellenbranda
Immunization Unit, Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany
Primary care pediatrician, Düsseldorfer Strasse 75, 40878 Ratingen, Germany
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 3 July 2014
eceived  in revised form
2 September 2014
ccepted  15 September 2014
vailable online 1 October 2014
a  b  s  t  r  a  c  t
Incidence  of  invasive  meningococcal  disease  is  low  in Germany  at 0.5  cases/100,000  inhabitants.
Serogroup  B (MenB)  is  most  common,  causing  70%  of  cases,  with  highest  incidence  in  infants
(5.9/100,000).  In 2013,  a MenB  vaccine  was  licensed  in Europe.  To  assess  pediatricians’  attitudes  towards
MenB  vaccination  and its potential  use  in  Germany  we conducted  a  nationwide  cross-sectional  survey
among  5677  pediatricians.  Of 3107  participants  (response:  55%),  79.1%  would  recommend  a MenB  vac-
cination  to parents,  with  66.7%  favoring  a schedule  at 6, 8 and 12 months  over 2,  3,  4  and  12  months
(13.4%). Administration  separately  from  other  vaccines  was preferred  (63.2%);  38.5% feared  that  a  rec-eywords:
eisseria meningitidis
eningococcal B vaccine
cceptance
mmunization  schedule
hildren
urvey
ommendation  would  lead  to  refusal  of  other  recommended  vaccinations.  In  conclusion,  pediatricians
showed  distinct  preferences  regarding  possible  integration  of MenB  vaccination  into  the  existent  immu-
nization  schedule.  As  physicians  play  a crucial  role in  the  implementation,  ﬁndings  will  be  useful  in
decision-making  regarding  potential  introduction.
©  2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).. Background
In Germany, the incidence of invasive meningococcal disease
IMD) has shown a decreasing trend since 2003, with a mean
nnual incidence of 0.5 cases/100,000 inhabitants in 2009–2011.
his is lower than the mean incidence in Europe of 0.8 in 2011,
nd markedly lower than in Ireland (2.0), the UK (1.7) or Spain
1.0) [1]. Approximately 70% of IMD  was caused by meningococcal
erogroup B (MenB), with a case-fatality of 8.2% [2]. MenB IMD  inci-
ence was highest in infants (mean: 5.9/100,000; 16% of all cases),
ollowed by 1, 2 and 15–19 year olds (3.3, 1.7 and 1.1/100,000,
espectively). Of cases in infants, 48% occurred in the ﬁrst 6 months
f life. Longterm sequelae such as hearing loss, neurological defects
r amputations have been reported in up to ∼20% of cases [3,4].
In  January 2013, the European Medicines Agency licensed
CMenB (Bexsero®), a novel multi-component MenB vaccine based
n subcapsular proteins [5]. Strain coverage for Germany was  esti-
ated at 82% [6]. In pre-licensure studies, the vaccine induced
atisfactory immunogenicity; but deﬁnitive data on effect on
∗ Corresponding author. Tel.: +49 30 18754 3483; fax: +49 30 18754 3533.
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ellenbrandW@rki.de (W.  Hellenbrand).
ttp://dx.doi.org/10.1016/j.vaccine.2014.09.040
264-410X/© 2014 The Authors. Published by Elsevier Ltd. This is an open access article unmeningococcal carriage, vaccine effectiveness and rare adverse
events are still pending [7]. The number of required doses varies
from 2 to 3 primary immunizations with/without 1 booster,
depending on age at ﬁrst dose [8]. Reactogenity of Bexsero® is
increased particularly in infants when administered concomitantly
with routine vaccines (Infanrix hexa® and Prevenar®) compared to
routine vaccines only or Bexsero® only [9].
Bexsero® was  marketed in Germany in December 2013. To
be included in the German national immunization schedule and
reimbursed by statutory health insurance, a new vaccine must be
recommended by the German Standing Committee on Vaccination
(STIKO). STIKO recommendations are ofﬁcially endorsed by 15 of
the 16 federal states. While not legally binding, these recommenda-
tions are considered the medical standard in liability cases [10]. The
currently recommended infant immunization schedule is shown
in Fig. 1. Childhood immunizations are almost exclusively admin-
istered by privately practicing pediatricians on a fee-for-service
basis [11]. In developing evidence-based recommendations, STIKO
follows a standard operating procedure to evaluate all available
evidence on vaccine efﬁcacy/effectiveness and safety, but also on
other aspects, such as implementability of the potential recom-
mendation, including possible obstacles and likely acceptance of
the vaccine [12]. Physicians play a crucial role for acceptance: in
a representative survey among parents in Germany, 93% indicated
that the physician was the main source of information regarding
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 1. Current routine vaccination schedule for infants 0–14 months as recommended by the German Standing Committee on Vaccination (STIKO), including the potential,
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Rurrently not recommended meningococcal B vaccinations (in red) at months 2, 3, 4
accination (diphtheria, tetanus, polio, pertussis, Haemophilus inﬂuenzae type b
accination, MenC—meningococcal C vaccination, Pnc—pneumococcal vaccination,
accination [13]. Another German study found that physicians’
ttitudes toward vaccination are predictive of vaccination cover-
ge [14]. Similarly, a survey in Australia described that parents’
otential willingness to have their child receive Bexsero® was  most
trongly inﬂuenced by a recommendation of the family doctor [15].
The aim of our study was to assess attitudes among pediatricians
owards MenB vaccination and its potential use in Germany, with
n emphasis on the perceived need for such a vaccine, the feasi-
ility of integrating it into the existing immunization schedule and
ossible implications for other routine childhood vaccinations.
.  Material and methods
In  November 2013, we conducted a nationwide cross-sectional
urvey among the 5677 privately practicing pediatricians with
embership in the German Professional Association for Pediatrici-
ns (BVKJ), representing 96% of all privately practicing pediatricians
n Germany [16].
A  written questionnaire was developed that included items on
articipants’ demographics (age, sex, practice location, years spent
n pediatric practice and board certiﬁcation status), as well as on
heir views regarding a possible MenB vaccine recommendation
nd administration (Table 1). The questionnaire was pre-tested by
5 pediatricians and subsequently posted to all eligible members,
ccompanied by a cover letter and one-page background informa-
ion on Bexsero® and MenB IMD  epidemiology in Germany.
Returned questionnaires were double-entered electronically
sing EpiData version 3.1 (EpiData Association, Denmark). A
escriptive analysis was performed, including calculation of pro-
ortions and 95% conﬁdence intervals (CI). Demographic data on
articipants were compared to available BVKJ-member informa-
ion. Due to Germany’s geographical size and historical differences,
e performed regional analyses. We  explored associations using
he Chi-squared Test and univariate logistic regression, followed
y stratiﬁcation for duration in private practice, sex and region to
stimate odds ratios (ORs) with 95% CIs. Statistical analysis was
erformed using Stata® version 13 (StataCorp, Texas, USA)..  Results and discussion
Of  the 5677 questionnaires sent out, 3107 (55%) were returned.
espondents’ mean age was 53 years (all BVKJ-members: 54 years),2 (Option 1) and at months 6, 8 and 12 (Option 2). Abbreviations: Hexa—hexavalent
epatitis B), MMR—measles mumps  rubella vaccination, MenB—meningococcal B
otavirus vaccination.
52%  were male (all members: 50%), and response ranged from
53–58% per region. Mean duration in pediatric practice was 16
years, and 99% (n = 3070) were board-certiﬁed pediatricians.
Participants’ responses are summarized in Table 1. The majority
(79.1%) stated they would recommend MenB vaccination. The most
common reasons given for not recommending the vaccine were a
concern that the schedule would become overcrowded and insuf-
ﬁcient data on potential rare adverse events. Children ≤24 months
were most frequently speciﬁed as target groups for MenB vacci-
nation, in keeping with the highest incidence at these ages. Two
thirds of participants believed that parents would be acceptant of
an ofﬁcial STIKO recommendation.
Of  two possible licensed vaccine schedules integrating MenB
vaccination into the current German routine immunization sched-
ule, vaccination at month 6, 8 and 12 of age (Option 2, Fig. 1)
was preferred by 66.7% of physicians (95%CI 65.0–68.3; n = 2070),
whereas vaccination at month 2, 3, 4 and 12 (Option 1, Fig. 1) was
favored by only 13.4% (95%CI 12.2–14.6; n = 416). Neither sched-
ule was chosen by 14% (95%CI 13.0–15.5; n = 441). Of these, 59.6%
(95%CI 54.9–64.3%; n = 263) indicated they would vaccinate in the
ﬁrst 6 months of life but at different time points than in Option 1.
In keeping with the strong preference for Option 2, only 31.3% of
all respondents thought MenB vaccination should be administered
concomitantly with other standard vaccinations. Similarly, >70% of
all participants objected in principle to the simultaneous admin-
istration of 3 vaccines; 19.7% among those favoring Option 1 and
81.8% among those favoring Option 2 (p < 0.005). The most common
reason given for objection was  lack of parental acceptance (Table 1).
Approximately 40% of all respondents thought that recom-
mendation of MenB vaccine would lead to refusal of other
recommended vaccinations (Table 1). It seems surprising that
physicians thought parents would most likely forego pneumococ-
cal vaccination if MenB vaccination were introduced, since this
is a disease at least as severe as MenB IMD  with a higher pre-
vaccination incidence [17], but maybe less in the focus of privately
practicing than of hospital-based pediatricians [18]. However, the
other three vaccines named in this context either protect against
diseases that are perceived as less severe (rotavirus, varicella) or
with a lower risk of infection than MenB IMD  (MenC).
Age, sex, region and years spent in pediatric practice had a
signiﬁcant effect on some of the responses (Table 2). As age
of pediatrician and years in practice were highly correlated
A. Takla et al. / Vaccine 32 (2014) 6349–6355 6351
Table  1
Survey results among privately practicing pediatricians (n = 3107), November 2013, Germany.
Item n % 95% CIc
If a MenBa vaccine were available: Would you recommend the vaccination to parents for their child (irrespective of an inclusion in the national immunization schedule)?
Yes  2456 79.1 77.6–80.5
For  what age groups?b
<12 months 1874 76.3 74.6–78.0
12–23  months 1389 56.6 54.6–58.5
2–11  years 850 34.6 32.7-36.5
12–17  years 918 37.4 35.5–39.3
≥18  years 269  11.0 9.7–12.3
No  345 11.1 10.0–12.3
Why  not?b
Would make vaccination schedule too crowded 187 54.1 48.6–59.4
Data  on rare adverse events insufﬁcient 163 47.1 41.8–52.5
Disease  is too rare 81 23.4 19.0–28.2
Vaccination  causes too many adverse events 55  15.9 12.2–20.2
Don’t  know 259 8.3 7.4–9.4
Do  you believe that parents will be acceptant of an ofﬁcial recommendation for routine MenBa vaccination of infants?
Yes  2077 66.9 65.2–68.5
No  371 11.9 10.8–13.1
Don’t  know 620  20.0 18.6–21.4
If  MenBa vaccination is adopted in the routine immunization schedule:How should infants be vaccinated against meningococcal B?
Separately from other recommended standard vaccinations 1963 63.2 61.5–64.9
Both  options (concomitant and separately) are acceptable 761 24.5 23.0–26.0
Concomitantly with hexavalent and pneumococcal vaccination 210 6.8 5.9–7.7
Don’t  know 111 3.6 2.9–4.3
Would  you conceivably administer three vaccines simultaneously to infants and toddlers at one visit?
Yes  662 21.3 19.9–22.8
No  2293 73.8 72.2–75.3
Why?b
Lack of parents’ acceptance 2053 89.5 88.2–90.6
Too  hard on the child 1611 70.3 68.3–72.1
Potential  adverse events cannot be attributed clearly to one/the new vaccine 1384 60.4 58.3–62.4
Causes  increased reactogenity that I would not want to risk 1313 57.3 55.2–59.3
Not  compatible with practice logistics 146 6.4 5.4–7.4
Don’t  know 133 4.3 3.6–5.1
Do  you fear that integration of the MenBa vaccine into the routine vaccination schedule for infants <1 year would lead to a refusal of other recommended vaccines?
Yes  1195 38.5 36.7–40.2
Which  ones?b
Pneumococcal vaccine 568 47.5 44.6–50.4
Rotavirus  455 38.0 35.3–40.9
Meningococcal C 431 36.0 33.3–38.8
Varicella  418 35.0 32.2–37.7
Hexavalent  vaccine 53 4.4 3.3–5.8
Measles–Mumps–Rubella 31 2.6 1.8–3.7
Don’t  know 196 16.4 14.3–18.6
No  1612 51.9 50.1–53.7
Don’t  know 269 8.7 7.7–9.7
a MenB: meningococcal serogroup B.
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c CI: conﬁdence interval.
Pearson’s correlation coefﬁcient = 0.83, p < 0.005), we  present
esults only for the latter. Female physicians and physicians in
ractice ≥10 years were less likely to fear refusal of other rec-
mmended vaccines if MenB vaccination were introduced, but
ere more likely to object to simultaneous administration of three
accines or concomitant MenB vaccination and other vaccines. Cor-
espondingly, female physicians were less likely to prefer Option 1
han their male colleagues, especially females in practice >10 years
see Appendix).
Compared to pediatricians from Northern states, pediatricians
rom Western and Eastern states were more likely and pediatrici-
ns from Southern states less likely to believe that parents would
e acceptant of MenB vaccination. Southern pediatricians were
lso more likely to fear refusal of other vaccines if MenB vacci-
ation were recommended, particularly if in practice <10 years,
hile those in Eastern states were less likely to fear this, partic-
larly those in practice ≥20 years (Appendix). This corresponds
ith a lower uptake of standard vaccines in Southern states thanin  other parts of Germany [19], possibly explained by a higher per-
centage of anthroposophists/vaccine-sceptics in their population
[20,21] and a less positive physicians’ attitude towards vaccination
[14]. In contrast, uptake of standard vaccines is highest in Eastern
Germany [19], where pediatricians, particularly female pediatrici-
ans (Appendix), were most likely to recommend MenB vaccination.
Nonetheless, Eastern pediatricians were also more likely to object
to simultaneous administration of 3 vaccines and prefer Option 2.
Regional differences among German physicians were also seen in
a previous study regarding attitude towards pertussis and measles
vaccination [14].
As  physicians play a crucial role in the implementation and
acceptance of new vaccines, assessment of their views is essen-
tial. So far, results from only one other study, conducted in
2012 in France, are available on the attitude of pediatricians
and general practitioners towards MenB vaccination [22]. In this
study, 96% of responding physicians thought MenB vaccination
important, but 81% were against administering three vaccines
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Table  2
Inﬂuence of length of time in practice, sex and region of private practice on pediatricians’ responses. Only variables with statistically signiﬁcant associations in univariate
analysis are shown.
Item N % OR 95% CIc
Would recommend MenBa vaccination to parents
Regionb
North 369 86.0 Ref –
West  810 88.2 1.22 0.87–1.71
East  485 92.4 1.97 1.29–3.01
South  744 85.4 0.95 0.68–1.33
In  favor of administering MenBa vaccination concomitantly with the hexavalent and pneumococcal vaccine
Length of practice time
<10 years 276 36.8 Ref –
10–19  years 343 33.8 0.88 0.72–1.07
≥20  years 349 30.5 0.75 0.62–0.92
Sex  of pediatrician
Female 404 29.0 Ref –
Male  565 37.0 1.44 1.23–1.68
Would  conceivably administer 3 injections to infants and toddlers at one visit
Length of practice time
<10 years 215  28.9 Ref –
10–19  years 220 21.6 0.68 0.54–0.84
≥20  years 225 19.2 0.58 0.47–0.72
Sex  of pediatrician
Female 222 15.9 Ref –
Male  438 28.1 2.06 1.72–2.47
Regionb
North 120 26.6 Ref –
West  235 24.2 0.88 0.69–1.14
East  75 13.8 0.44 0.32–0.61
South  652 22.5 0.86 0.67–1.12
Preference  for schedule Option 1 (MenBa vaccine doses at 2, 3, 4 and 12 months)
Sex  of pediatrician
Female 155 13.5 Ref –
Male  260 19.6 1.56 1.26–1.94
Regionb
North 78 20.6 Ref –
West  138 16.8 0.78 0.57–1.06
East  54 12.3 0.54 0.37–0.79
South  142 17.8 0.84 0.61–1.14
Belief  that parents will be acceptant of routine infant MenBa vaccination
Sex  of pediatrician
Female 992 86.9 Ref –
Male  1078 83.2 0.75 0.60–0.94
Regionb
North 310 82.2 Ref –
West  732 89.6 1.86 1.32–2.63
East  431 92.1 2.52 1.64–3.86
South  567 76.9 0.72 0.53–0.99
Fear  that MenBa vaccination will lead to refusal of other recommended vaccines
Length  of practice time
<10 years 348 49.7 Ref –
10–19  years 441 44.6 0.82 0.67–0.99
≥20  years 388 35.6 0.56 0.46–0.68
Sex  of pediatrician
Female 512 39.0 Ref –
Male  675 45.5 1.31 1.12–1.52
Regionb
North 188 43.6 Ref –
West  366 39.6 0.85 0.67–1.07
East  173 34.0 0.67 0.51–0.87
South  441 49.6 1.27 1.01–1.60
a MenB: meningococcal serogroup B.
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wb Regions were deﬁned as following: North (federal states of Bremen, Hamburg
alatinate, Saarland), East (Berlin, Brandenburg, Mecklenburg-Western Pomerania,
c CI: conﬁdence interval.
imultaneously and 54% favored administering MenB vaccine sep-
rately from other vaccinations—results comparable to ours. Thus,
he addition of Bexsero® to an already busy vaccination schedule
ppears challenging, at least in the ﬁrst 6 months of life, primar-
ly due to widespread reluctance to administer three injections
imultaneously and thus to administer Bexsero® concomitantly
ith currently recommended standard vaccines. Moreover, 90%r Saxony, Schleswig-Holstein), West (Hesse, North Rhine-Westphalia, Rhineland-
y, Saxony-Anhalt, Thuringia) and South (Baden-Württemberg, Bavaria).
of  pediatricians who  objected to three simultaneous injections
believed that parents would also object to this. A recent review of
mostly North American studies on provider and parental attitudes
towards multiple injections [23] showed that provider acceptance
of >2 injections increased when ofﬁcial recommendations required
this. Providers also tended to overestimate parental concern, and
reassurance by physicians as well as an understanding of the
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everity of the target disease increased parental acceptance of mul-
iple injections. While parental objection to >2 injections per visit
as also reported in a recent study from The Netherlands [24], with
 majority of parents preferring an extra visit, half said they would
robably accept three vaccinations if actually offered. Similarly,
he Australian survey showed that a third injection per visit made
nly 15% of parents less likely to want MenB vaccine for their child
15]. However, none of the studies, including the latter, explicitly
nvestigated whether parental acceptance for concomitant vac-
ination would be affected by the information that concomitant
accination was shown to be more reactogenic than alternating
njections.
Taken together, our results suggest that if STIKO should rec-
mmend MenB vaccination for infants from 2 months of age
n completion of the evidence assessment, it would be essen-
ial to provide pediatricians with a convincing rationale and
trong arguments for concomitant vaccination, to ensure success-
ul implementation and to avoid the dropping of other equally or
ven more important vaccinations by physicians or parents. This
hould include evidence suggesting that parents can be convinced
o accept three simultaneous injections by their physicians. Since
enB incidence is highest in the ﬁrst year of life, with about half
f cases occurring <6 months of age, early vaccination would pre-
ent the most cases. Nonetheless, in Germany 59% of cases in the
rst 3 years of life occur in children aged 9 months and older, the
ge-span in which protection would be expected using the later
-dose schedule. An additional 21% of cases in children <3 years of
ge occur in children from 5 to 8 months of age (unpublished data,
able A1
nﬂuence of length of time in practice, sex and region of private practice on pediatricians’
resented  only when odds ratios in strata differed markedly from those of the univariate
Item N 
Would recommend MenBa vaccination to parents
Length of practice time
<10 years 617 
10–19  years 870 
≥20  years 948 
Sex  of pediatrician
Female 1141 
Male  1306 
Regionb
North 369 
West  810 
East  485 
South  744 
Regionb by sex: males
North 204 
West  507 
East  108 
South  465 
Regionb by sex: females
North 163 
West  301 
East  377 
South  279 
In  favor of administering MenBa vaccination concomitantly with the hexavalent and pneum
Length of practice time
<10 years 276 
10–19  years 343 
≥20  years 349 
Sex  of pediatrician
Female 404 
Male  565 
Regionb
North 163 
West  336 
East  162 
South  296  (2014) 6349–6355 6353
Robert Koch Institute), potentially preventable through earlier vac-
cination. Thus, in view of the currently low incidence in Germany
and overwhelming preference for administration of MenB vaccine
separately from routine vaccines, implementation at a later age,
requiring fewer doses, might lead to higher uptake and thereby
have similar or higher impact. A modeling exercise comparing
the impact of different vaccination strategies at the population
level is currently being carried out for Germany and will inform
STIKO decision-making in addition to other data such as the results
derived from the present survey.
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Table  A1.
 responses in univariate and stratiﬁed analysis. Results of the stratiﬁed analysis are
 analysis.
% OR 95% CIc
88.5 Ref –
89.3 1.08 0.80–1.48
86.0 0.79 0.59–1.06
87.5 Ref –
88.0 1.04 0.83–1.31
86.0 Ref –
88.2 1.22 0.87–1.71
92.4 1.97 1.29–3.01
85.4 0.95 0.68–1.33
88.3 Ref –
90.2 1.22 0.75–1.99
90.0 1.19 0.58–2.44
85.2 0.76 0.48–1.21
83.2 Ref –
85.3 1.17 0.73–1.89
93.1 2.73 1.59–4.66
85.9 1.23 0.75–2.00
ococcal vaccine
36.8 Ref –
33.8 0.88 0.72–1.07
30.5 0.75 0.62–0.92
29.0 Ref –
37.0 1.44 1.23–1.68
35.8 Ref –
35.0 0.97 0.77–1.22
29.9 0.77 0.59–1.00
32.2 0.85 0.67–1.08
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Table  A1 (Continued)
Item N % OR 95% CIc
Would conceivably administer 3 injections to infants and toddlers at one visit
Length of practice time
<10 years 215 28.9 Ref –
10–19  years 220 21.6 0.68 0.54–0.84
≥20  years 225 19.2 0.58 0.47–0.72
Sex  of pediatrician
Female 222 15.9 Ref –
Male  438 28.1 2.06 1.72–2.47
Regionb
North 120 26.6 Ref –
West  235 24.2 0.88 0.69–1.14
East  75 13.8 0.44 0.32–0.61
South  652 22.5 0.86 0.67–1.12
Preference  for schedule Option 1 (MenBa vaccine doses at 2, 3, 4 and 12 months)
Length  of practice time
<10 years 121 18.0 Ref –
10–19  years 134 15.8 0.86 0.65–1.12
≥20  years 160 16.9 0.92 0.71–1.20
Sex  of pediatrician
Female 155 13.5 Ref –
Male  260 19.6 1.56 1.26–1.94
Regionb
North 78 20.6 Ref –
West  138 16.8 0.78 0.57–1.06
East  54 12.3 0.54 0.37–0.79
South  142 17.8 0.84 0.61–1.14
Length  of practice time by sex: males
<10 years 59 17.9 Ref –
10–19  years 39 10.5 1.13 0.79–1.61
≥20  years 56 12.6 1.17 0.82–1.65
Length  of practice time by sex: females
<10 years 62 18.1 Ref –
10–19  years 95 20.0 0.54 0.35–0.83
≥20  years 103 20.5 0.66 0.44–0.98
Belief  that parents will be acceptant of routine infant MenBa vaccination
Length of practice time
<10 years 518 85.2 Ref –
10–19  years 719 84.0 0.91 0.68–1.22
≥20  years 827 85.8 1.05 0.79–1.40
Sex  of pediatrician
Female 992 86.9 Ref –
Male  1078 83.2 0.75 0.60–0.94
Regionb
North 310 82.2 Ref –
West  732 89.6 1.86 1.32–2.63
East  431 92.1 2.52 1.64–3.86
South  567 76.9 0.72 0.53–0.99
Fear  that MenBa vaccination will lead to refusal of other recommended vaccines
Length  of practice time
<10 years 348 49.7 Ref –
10–19  years 441 44.6 0.82 0.67–0.99
≥20  years 388 35.6 0.56 0.46–0.68
Sex  of pediatrician
Female 512 39.0 Ref –
Male  675 45.5 1.31 1.12–1.52
Regionb
North 188 43.6 Ref –
West  366 39.6 0.85 0.67–1.07
East  173 34.0 0.67 0.51–0.87
South  441 49.6 1.27 1.01–1.60
Regionb by length of practice time: <10 years
North  55 44.4 Ref –
West  98 44.3 1.00 0.64–1.56
East  52 44.8 1.02 0.61–1.70
South  135 60.0 1.88 1.21–2.93
Regionb by length of practice time: ≥20 years
North  63 41.7 Ref –
West  118 33.8 0.71 0.48–1.06
East  69 26.5 0.50 0.33–0.77
South  132 42.2 1.02 0.69–1.51
a MenB: meningococcal serogroup B.
b Regions were deﬁned as following: North (federal states of Bremen, Hamburg, Lower Saxony, Schleswig-Holstein), West (Hesse, North Rhine-Westphalia, Rhineland-
Palatinate, Saarland), East (Berlin, Brandenburg, Mecklenburg-Western Pomerania, Saxony, Saxony-Anhalt, Thuringia) and South (Baden-Württemberg, Bavaria).
c CI: conﬁdence interval.
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